-

Onco360® Selected by Merck & Co., Inc. to Be in Specialty Pharmacy Network for WELIREG™ (belzutifan)

LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by Merck & Co., Inc. to be in the specialty pharmacy network for WELIREG (belzutifan), a hypoxia-inducible factor inhibitor indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

“Onco360 is honored to be included in the Merck specialty pharmacy network for WELIREG,” said Benito Fernandez, Chief Commercial Officer, Onco360. “Onco360 is committed to supporting von Hippel-Lindau patients afflicted with certain associated tumors requiring treatment.”

About Onco360®, Oncology Pharmacy:

Onco360 is the largest independent Oncology Pharmacy and clinical support services company in the country. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com.

References

1) Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482) | Business Wire . Accessed August 2021.
2) Von Hippel-Lindau disease | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program (nih.gov) . Accessed August 2021.
3) Kidney and Renal Pelvis Cancer — Cancer Stat Facts . Accessed August 2021. Accessed August 2021.

Contacts

Benito Fernandez, Chief Commercial Officer
benito.fernandez@onco360.com
516-640-1332

Industry:

Onco360

Release Versions
English

Contacts

Benito Fernandez, Chief Commercial Officer
benito.fernandez@onco360.com
516-640-1332

More News From Onco360

Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO® (selinexor)

LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360®, the nation’s largest independent Oncology Pharmacy, is now the national specialty pharmacy network partner for Karyopharm’s product XPOVIO® (selinexor), a first-in-class, XPO-1 inhibitor. XPOVIO is approved in multiple oncology indications, including: (i) in combination with Velcade® (bortezomib) and dexamethasone (XVd) in patients with multiple myeloma after at least one prior therapy; (ii) in combination with dexamethasone in patients with heavily p...

FABHALTA (iptacopan) Now Available from Onco360 as the First FDA-Approved Oral Monotherapy Approved for the Treatment of Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Novartis for Fabhalta® (iptacopan) as the first oral monotherapy approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).1 Fabhalta® is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing control of red blood cell destruction within and outside the blood vessels (intra-...

OGSIVEO™ (nirogacestat) Now Available from Onco360 as the First and Only FDA-Approved Treatment for Adults with Progressing Desmoid Tumors Who Require Systemic Treatment

LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by SpringWorks Therapeutics for Ogsiveo™ (nirogacestat). Ogsiveo™ is an oral gamma secretase inhibitor for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. “Onco360 is excited to partner with the team at SpringWorks Therapeutics and become a specialty pharmacy partner for Ogsiveo™,” said Benito Fernandez, Chief Co...
Back to Newsroom